|
1
|
Black DL: Mechanisms of alternative
pre-messenger RNA splicing. Annu Rev Biochem. 72:291–336. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singh RK and Cooper TA: Pre-mRNA splicing
in disease and therapeutics. Trends Mol Med. 18:472–482. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pal S, Gupta R and Davuluri RV:
Alternative transcription and alternative splicing in cancer.
Pharmacol Ther. 136:283–294. 2012. View Article : Google Scholar
|
|
4
|
Garcia-Blanco MA, Baraniak AP and Lasda
EL: Alternative splicing in disease and therapy. Nat Biotechnol.
22:535–546. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mills AA: p53: link to the past, bridge to
the future. Genes Dev. 19:2091–2099. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lamolle G, Marin M and Alvarez-Valin F:
Silent mutations in the gene encoding the p53 protein are
preferentially located in conserved amino acid positions and
splicing enhancers. Mutat Res. 600:102–112. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Neklason DW, Solomon CH, Dalton AL, Kuwada
SK and Burt RW: Intron 4 mutation in APC gene results in splice
defect and attenuated FAP phenotype. Fam Cancer. 3:35–40. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mazoyer S, Puget N, Perrin-Vidoz L, Lynch
HT, Serova-Sinilnikova OM and Lenoir GM: A BRCA1 nonsense mutation
causes exon skipping. Am J Hum Genet. 62:713–715. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ghigna C, Valacca C and Biamonti G:
Alternative splicing and tumor progression. Curr Genomics.
9:556–570. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
David CJ and Manley JL: Alternative
pre-mRNA splicing regulation in cancer: pathways and programs
unhinged. Genes Dev. 24:2343–2364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bosch FX and Muñoz N: The viral etiology
of cervical cancer. Virus Res. 89:183–190. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Walboomers JM, Jacobs MV, Manos MM, et al:
Human papillomavirus is a necessary cause of invasive cervical
cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
zur Hausen H: Papillomaviruses and cancer:
from basic studies to clinical application. Nat Rev Cancer.
2:342–350. 2002.PubMed/NCBI
|
|
14
|
Muñoz N, Bosch FX, de Sanjosé S, et al:
Epidemiologic classification of human papillomavirus types
associated with cervical cancer. N Engl J Med. 348:518–527.
2003.
|
|
15
|
Muñoz N: Human papillomavirus and cancer:
the epidemiological evidence. J Clin Virol. 19:1–5. 2000.
|
|
16
|
Clifford GM, Smith JS, Plummer M, Muñoz N
and Franceschi S: Human papillomavirus types in invasive cervical
cancer worldwide: a meta-analysis. Br J Cancer. 88:63–73. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sundström K, Ploner A, Dahlström LA, et
al: Prospective study of HPV16 viral load and risk of in situ and
invasive squamous cervical cancer. Cancer Epidemiol Biomarkers
Prev. 22:150–158. 2013.PubMed/NCBI
|
|
18
|
Lazo PA: Papillomavirus integration:
prognostic marker in cervical cancer? Am J Obstet Gynecol.
176:1121–1122. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kalantari M, Karlsen F, Kristensen G, Holm
R, Hagmar B and Johansson B: Disruption of the E1 and E2 reading
frames of HPV 16 in cervical carcinoma is associated with poor
prognosis. Int J Gynecol Pathol. 17:146–153. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kalantari M, Blennow E, Hagmar B and
Johansson B: Physical state of HPV16 and chromosomal mapping of the
integrated form in cervical carcinomas. Diagn Mol Pathol. 10:46–54.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Romanczuk H and Howley PM: Disruption of
either the E1 or the E2 regulatory gene of human papillomavirus
type 16 increases viral immortalization capacity. Proc Natl Acad
Sci USA. 89:3159–3163. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McPhillips MG, Veerapraditsin T, Cumming
SA, et al: SF2/ASF binds the human papillomavirus type 16 late RNA
control element and is regulated during differentiation of
virus-infected epithelial cells. J Virol. 78:10598–10605. 2004.
View Article : Google Scholar
|
|
23
|
Cheunim T, Zhang J, Milligan SG,
McPhillips MG and Graham SV: The alternative splicing factor hnRNP
A1 is up-regulated during virus-infected epithelial cell
differentiation and binds the human papillomavirus type 16 late
regulatory element. Virus Res. 131:189–198. 2008. View Article : Google Scholar
|
|
24
|
Hellman K, Alaiya AA, Becker S, et al:
Differential tissue-specific protein markers of vaginal carcinoma.
Br J Cancer. 100:1303–1314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shimada K, Uzawa K, Kato M, et al:
Aberrant expression of RAB1A in human tongue cancer. Br J Cancer.
92:1915–1921. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun T, Wang X, He HH, et al: MiR-221
promotes the development of androgen independence in prostate
cancer cells via downregulation of HECTD2 and RAB1A. Oncogene.
33:2790–2800. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu SS, Chen XM, Zheng HX, Shi SL and Li
Y: Knockdown of Rab5a expression decreases cancer cell motility and
invasion through integrin-mediated signaling pathway. J Biomed Sci.
18:582011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheng KW, Lahad JP, Kuo WL, et al: The
RAB25 small GTPase determines aggressiveness of ovarian and breast
cancers. Nat Med. 10:1251–1256. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hutagalung AH and Novick PJ: Role of Rab
GTPases in membrane traffic and cell physiology. Physiol Rev.
91:119–149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hernández-Alcoceba R, del Peso L and Lacal
JC: The Ras family of GTPases in cancer cell invasion. Cell Mol
Life Sci. 57:65–76. 2000.PubMed/NCBI
|
|
31
|
Münger K, Baldwin A, Edwards KM, et al:
Mechanisms of human papillomavirus-induced oncogenesis. J Virol.
78:11451–11460. 2004.
|
